News

Back to Careers

CEO Dr. Hanadie Yousef discusses how the success of GLP-1/GIP receptor agonists is reshaping the treatment of chronic metabolic diseases and driving the next wave of therapeutics targeting the biology of aging at BIO 2025 in Boston